Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacteriophage phi X 174 is a small, tailless icosahedral virus belonging to the family Microviridae and genus Microvirus. It infects Escherichia coli (E. coli) bacteria and contains a circular single-stranded DNA (ssDNA) genome of approximately 5,386 nucleotides—the first DNA genome ever sequenced. The virion consists of a protein capsid composed mainly of F and G proteins with additional H and J proteins; the core contains the viral ssDNA. Upon infection, the phage attaches to E. coli via its G protein binding to lipopolysaccharides on the bacterial surface and injects its genome into the host cell using H protein as a pilot for DNA entry. Replication proceeds through synthesis of a complementary negative strand forming double-stranded intermediates that serve as templates for mRNA transcription and further ssDNA synthesis by rolling circle replication. Phi X 174 encodes overlapping genes due to its compact genome; key proteins include A (replication), B (capsid morphogenesis), C (phage maturation), D (assembly), E (host cell lysis via inhibition of peptidoglycan synthesis by targeting MraY enzyme in complex with SlyD from host), F/G/H/J/K structural or assembly roles. Clinically, bacteriophage phi X 174 is used as an investigational T cell-dependent neoantigen for assessing antibody responses in patients with suspected primary immunodeficiencies such as common variable immunodeficiency or hypogammaglobulinemia[6]. It also serves as a model organism in molecular biology research and quality control applications such as water testing[4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacteriophage phi X 174.